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Abstract
Purpose: Telomerase activity appears to play a crucial role in the development of many tumors. More than 80% of all malig-
nant human tumors show an increased telomerase activity. However, conflicting results have been reported about telomerase
activity in sarcomas. The aim of the study was to obtain more information about telomerase activity in sarcomas based on a
large number of cases.
Methods: Telomerase activity was measured in 69 different tumor samples (33 malignant bone tumors and 36 soft tissue
sarcomas). Tumor samples were obtained intraoperatively and frozen immediately in liquid nitrogen. Telomerase activity
was detected by the telomeric repeat amplification assay (TRAP-assay).
Results: Only 7% of the samples showed telomerase activity. No correlation between staging and telomerase activity could be
observed.
Discussion: The fact that only five out of 69 examined tumor samples showed a telomerase activity provides experimental
evidence that in sarcomas the reactivation of telomerase may play a subordinate role. Our results suggest that alternative
mechanisms for cell immortalization, yet to be determined, seem to be involved in the development and/or maintenance of
soft-tissue sarcomas and malignant bone tumors.
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Introduction
Telomerase is a  ribonucleoprotein that  synthesizes
G-rich telomeric repeats (TTAGGG) onto chromo-
somal ends. In this way, telomerase may help to com-
pensate for the gradual shortening of linear molecules
replicated by DNA polymerase and contribute to the
stability of chromosomes.
It  has  been  determined  that  telomerase  is
expressed  in  80–90%  of  human  tumors  but  only
rarely  in  normal  adult  tissue.  It  has  been  also
suggested that telomere shortening may be the mech-
anism underlying the ‘mitotic clock’  that  regulates
the  limit  of  normal  cell  divisions  and  determines
progression into senescence.1
Thus, the reactivation of telomerase should enable
malignant cells to bypass the normal growth arrest,
which is linked to an unlimited proliferation capacity
and to immortalization.
The  analysis  of  tumors  under the  aspect  of  an
increased telomerase activity was carried out with the
hope that this enzyme may become an indicator for
malignancy and prognosis as well as a target in the
therapy of cancer.
Many studies have described increased telomerase
activities in carcinoma cell lines as well as malignant
tumors of epithelial origin. However, different results
exist about telomerase activity in sarcomas.2–5 Fur-
thermore, these few already existing studies are based
on low number of cases.44 N. K. Lauer et al.
The present study is based on a larger number of
cases  and  different  types  of  tumors.  It  has  been
carried out in order to get more information about
telomerase activity in sarcomas.
Material and methods
Tissue samples
The examined tumor samples were obtained from 69
patients (45 males, 24 females) including 17 osteosa-
rcomas, 12 malignant fibrous histiocytomas (MFH),
nine  leiomyosarcomas,  seven  Ewing’s  sarcomas,
seven  liposarcomas,  six  chondrosarcomas,  three
chordomas, three fibrosarcomas, two rhabdomyosar-
comas, one clear cell sarcoma, one myxosarcoma and
one malignant  schwannoma. The tumor, which  is
listed  as  a  schwannoma, is  a  malignant  peripheral
nerve sheath tumor. A further (sub)classification of
the  rhabdomyosarcomas  was  not  performed.  The
specimens were taken from vital tumor regions and
two independent experienced pathologists confirmed
the diagnoses independently; there was no misdiag-
nosis. Tumor samples were obtained intraoperatively
and frozen immediately in liquid nitrogen. Then they
were stored at -70ºC until further use. Pathologists
had examined all tumors and thus the diagnosis was
confirmed.
TRAP-assay
Telomerase activity  was  detected by  the  telomeric
repeat amplification assay (TRAP-assay) using the tel-
omerase detection kit from Boehringer (Mannheim,
Germany) based on the method described by Kim
et al.6 It allows highly specific amplification of telom-
erase-mediated elongation products combined with
nonradioactive detection following a ELISA protocol.
Small frozen tissue samples were collected and dis-
solved in lysis buffer. The concentration of protein in
the supernatant was determined by using the BCA
protein assay kit (Pierce Chemical Co., Rockford, IL,
USA). The further procedure followed essentially the
instructions of the supplier (Boehringer Mannheim).
As  negative  control  a  duplicate  of  each  tissue
sample was used which was incubated at 75–80ºC for
10  min  (prior  to  the  TRAP-assay)  to  inactivate
telomerase. As positive control a telomerase-contain-
ing cell extract provided in the kit was used as well as
a defined telomerase-positive colon carcinoma. For
all tumor specimens, at least two samples were exam-
ined which were taken  from different parts  of  the
tumor. For the interpretation of the results the mean
of the absorbance readings of the negative controls
were subtracted from those of the samples. Samples
were regarded as telomerase-positive if the difference
in  absorbance  was  higher  than  0.2  A450nm  units.
Typical  positive  values  were  in  a  range  of
1.367–1.633.
Results
A total of 69 tumor samples from 69 patients were
examined  in  this  study.  According  to  Enneking’s
classification system of sarcoma7 most of the tumors
were  high  grade  and  extracompartmental  tumors
(stage IIb, n=44). Only six of the high-grade tumors
were located intracompartmental (stage IIa). Twelve
of the 13 low-grade tumors were also extracompart-
mental tumors (stage Ib).
In  six  cases  there  were  distant,  pulmonal
metastases  (stage  III).  Only  five  of  the  69  (7%)
showed telomerase activity (see Table 1). In detail
these were two Ewing’s sarcomas, one leiomyosar-
coma, one liposarcoma and one rhabdomyosarcoma
(see Table 2).
Table 1. Telomerase activity in malignant bone tumors (MBT) and soft tissue sarcoma (STS)
Stage (Enneking)2 Telomerase activity
n1 Tumor specimen n1 Ia Ib IIa IIb III +
MBT 33 Osteosarcoma 17 1 14 2 0/17
Ewing’s sarcoma 7 6 1 2/7
Chondrosarcoma 6 1 3 1 1 0/6
Chordoma 3 2 1 0/3
STS 36 MFH 12 3 9 0/12
Leiomyosarcoma 9 1 8 1/9
Liposarcoma 7 5 1 1 1/7
Fibrosarcoma 3 1 2 0/3
Rhabdomyosarcoma 2 1 1 1/2
Clear cell sarcoma 1 1 0/1
Myxosarcoma 1 1 0/1
Schwannoma 1 1 0/1
69 69 1 12 6 44 6 5/69
1n=number of tumor samples.
2Enneking’s surgical staging (7): I, low grade; II, high grade; III, distant metastasis (low grade or high grade); a, intracom-
partmental; b, extracompartimental.Absence of telomerase activity in sarcomas 45
In two tumors, in one of the Ewing’s sarcoma and in
the  rhabdomyosarcoma, there  were  distant  metas-
tases presented at the time of diagnosis. Two tumors,
one  of  the  Ewing’s  sarcomas and  the  leiomyosar-
coma, were of stage IIb, whereas the liposarcoma was
a high-grade intracompartmental tumor.
Thus, all positives were found amongst high-grade
tumors, whereas no low-grade tumor expressed telom-
erase activity. These findings could lead to the con-
clusion that high telomerase activity may be related to
the high proliferative state of these tumors. However,
this difference was statistically not significant.
Discussion
During the past decade many studies dealing with
telomerase activity  in carcinoma have been carried
out. These studies have shown that the reactivation of
telomerase seems to be a dominating mechanism in
the oncogenesis of these tumors. Up to now little is
known about sarcoma and telomerase activity. The
low number of already existing studies dealing with
this question are based on a small number of cases
and show contradictory results.2 For example Aue
et al.2  reported  telomerase  activity  in  eight  of  14
skeletal  sarcoma samples, whereby the  majority  of
osteosarcomas showed no telomerase activity. Bryan
et al.4 found mainly no telomerase activity in tumor
cells  derived  from  sarcoma.  Our  results  are  in
line with recent findings that only a few soft tissue
sarcomas display telomerase activity.2,8
In the present study these results have been verified
based on a larger number of cases as well as different
types of sarcoma. The fact that only five out of 69
examined tumor samples showed telomerase activity
confirms the impression that in sarcomas the reacti-
vation of telomerase plays only a subordinate role.
Consequently, in the  oncogenesis of  mesenchymal
tumors other mechanisms for immortalization seem
to be of decisive importance. Although there is a lot
of different tumor types of soft tissue sarcomas and
malignant bone tumors, there is a tendency that most
of these tumors are telomerase-negative. It is also well
known in soft tissue and bone sarcomas that there is
a marked heterogeneity throughout the tissue, but all
tumors were examined by an experienced pathologist
and  an  independent  pathologist  confirmed  the
diagnosis. And overall there was no misdiagnosis.
Some authors have  already  postulated the  exist-
ence of one or several such mechanisms. Examina-
tion of a series of various immortal cell lines provided
evidence that telomere elongation can occur without
measurable  telomerase  activity.9–13  These  mecha-
nisms, which are still basically unknown, were called
ALT (alternative  lengthening of telomeres). Up to
now various alternative pathways for telomere main-
tenance have been discussed, such as an intermittent
telomerase activity or telomere–telomere recombina-
tion  that  is  known  from  the  yeast  Saccharomyces
cerevisiae  (summarized  in  Ref.  14).  A  new  link
between telomere maintenance and mismatch repair
was  recently  published.15  It  was  proposed  that
enhanced telomeric recombination in cells with mis-
match-repair defects may contribute to cell immor-
talization  and  hence  tumorigenesis.  However,  the
molecular mechanisms underlying these phenomena
are currently unknown.
In the  course of  some  studies4–6  it  has  become
obvious that all cell lines derived from sarcomas or
immortalized  fibroblasts  were  ALT-positive.  This
observation  is in  clear contrast to  the  situation  in
epithelial cell lines, which show only rarely ALT. A
possible  explanation  for  this  difference  between
epithelial and mesenchymal cells and consequently
between carcinoma and sarcoma may be their origin
from different germ layers.
Another fact worth mentioning is the observation
of some authors that sarcoma often show a shortened
telomere length.3,16 This could be the result of the
lack of telomerase activity in the majority of sarcoma.
Further studies will have to be carried out in order to
trace the exact mechanism and differences of tumor
growth in the case of sarcoma in contrast to carci-
noma. Such differences might be of vital importance
for the development of therapeutical measures.
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